h for CBD and placebo. CBD's activity in schizophrenia is supported by pre-clinical data in animal models, as well as by a recent study published in The Journal of Clinical investigations (2012) which suggested CBD may be useful as either monotherapy or in combination with first line anti-psychotic agents. Nonetheless, while the p-valu